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Abstract: Hypertension treatment and control is largely unsatisfactory when guideline-defined 
blood pressure goal achievement and maintenance are considered. Patient- and physician-related 
factors leading to non-adherence interfere in this respect with the efficacy, tolerability, and 
convenient use of pharmacological treatment options. Blockers of the renin–angiotensin system 
(RAS) are an important component of antihypertensive combination therapy. Thiazide-type 
diuretics are usually added to increase the blood pressure lowering efficacy. Fixed drug–drug 
combinations of both principles like candesartan/hydrochlorothiazide (HCTZ) are highly 
effective in lowering blood pressure while providing improved compliance, a good toler-
ability, and largely neutral metabolic profile. Comparative studies with losartan/HCTZ have 
consistently shown a higher clinical efficacy with the candesartan/HCTZ combination. Data 
on the reduction of cardiovascular endpoints with fixed dose combinations of antihypertensive 
drugs are however scarce, as are the data for candesartan/HCTZ. But many trials have tested 
candesartan versus a non-RAS blocking comparator based on a standard therapy including 
thiazide diuretics. The indications tested were heart failure and stroke and particular emphasis 
was put on elderly patients or those with diabetes. In patients with heart failure, for example, 
the fixed dose combination might be applied in patients in whom individual titration resulted 
in a dose of 32 mg candesartan and 25 mg HCTZ which can then be combined into one tablet 
to increase compliance with treatment. Also in patients with stroke the fixed dose combination 
might be used in patients in whom maintenance therapy with both components is considered. 
Taken together candesartan/HCTZ assist both physicians and patients in achieving long-term 
blood pressure goal achievement and maintenance.
Keywords: chronic heart failure, stroke, diabetes, angiotensin receptor blocker, patients, 
physicians, persistence, compliance
Background
Hypertension is a highly prevalent risk factor for coronary heart disease (CHD), stroke, 
heart failure (HF), renal disease, and recurrent cardiovascular events. It has been shown 
to reduce the number of life-years lost and the number of years lived with disability 
by 64.3 million globally.1 The European Society of Hypertension (ESH) classifies 
optimal blood pressure at 120 mmHg systolic blood pressure (SBP), and 80 mmHg 
diastolic blood pressure (DBP).2
A therapeutic reduction of elevated blood pressure (BP) levels has been shown to 
decrease cardiovascular morbidity and mortality.3 For the pharmacological management Vascular Health and Risk Management 2009:5 1044
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of hypertension, lowering BP below 140/90 mmHg in all 
patients is requested. Specific patients, those with diabetes 
mellitus or chronic kidney disease, need further BP reduction 
(130/80 mmHg or 125/75 mmHg, respectively).
However these BP targets are difficult to meet despite the 
availability of a number of effective antihypertensive drugs. 
Consequently hypertension control is largely ineffective as 
the achievement of guideline defined treatment targets with 
about 20% of patients in Europe and up to 50% of patients 
in the US being finally controlled when treated.4,5 BP target 
achievement is even worse in patients with comorbid 
disease like diabetes mellitus.
Patient perspective
Hypertension is a rather unspectacular disease with unspe-
cific symptoms that are, from a patient perspective, in many 
cases not perceived to occur in relation to hypertension. 
Patients therefore are reluctant to accept physicians’ recom-
mendations to adopt life-style changes (weight reduction, 
reduction of sodium intake, and increased physical activity), 
which are the recommended first steps in the treatment of 
hypertension.
It becomes even more difficult to convince patients for 
the need of action when antihypertensive pharmacotherapy is 
introduced. A number of patient-related factors leading to non-
adherence like frequent dosing,6,7 drug-related adverse events 
(AEs),8 health beliefs,9 drug–drug interactions and associated 
medical conditions interfere with the patients’ willingness 
to take drugs as prescribed. For an overview of terms used 
to describe adherence see Figure 1. Actually approximately 
half of the patients on antihypertensive drug therapy 
discontinue therapy by the end of the first year.
Hence, from a patient perspective, there is a need for 
effective, highly tolerable and convenient medication 
that does not interfere with daily life while controlling 
hypertension-associated risk.
Physician perspective
Recent data suggest that also physicians’ attitudes and 
treatment strategies hamper the effectiveness of current 
therapy.10–12 In a recent global survey in a random sample of 
primary care physicians, 41% of physicians aimed to reduce 
BP to “acceptable levels” only, although generally agreeing 
with guideline recommended treatment goals. Physicians 
further believed that 62% of their patients had their BP 
controlled. However, in fact only 6% of patients with hyper-
tension in the UK had their BP lowered to the recommended 
levels.13 In France, Germany, Italy, and Spain only 13% of 
hypertensive patients have their BP controlled.14
The physicians’ needs in the treatment of hypertension 
are partially overlapping with patients’ needs. However, in 
the face of low patient compliance, the chronic nature of the 
disease, and increasing budget constraints, a possible solution 
seems to be difficult to determine.
Treatment patterns
Globally about one-third of patients receive monotherapy, 
one-third dual combination therapy, and one-third 3 or more 
Adherence
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Figure 1 Terms used to describe adherence.Vascular Health and Risk Management 2009:5 1045
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antihypertensive drugs. The NICE for example calculated 
that 36% of patients in the UK receive monotherapy, 38% 
dual combination therapy, and 26% 3 or more drug–drug 
combinations.15 In a recent drug utilization analysis in 
primary care in Germany, 29.2% of treated patients received 
one, 43.7% received 2, and 27.2% received 3 or more anti-
hypertensive drugs.16
According to the aforementioned study16 40.8% of 
patients in Germany received ACE inhibitors (ACEi), 36.1% 
beta blockers, 31.7% diuretics, 22.3% calcium channel 
blockers (CCBs) and 14.1% angiotensin receptor blockers 
(ARBs).16 Frequent drug–drug combinations were ACEi 
or ARBs in combination with diuretics, CCBs, and beta 
blockers which is mostly in accordance with recent guide-
lines in which 4 out of 6 recommended combinations are 
ACEi/ARB based.17
Guidelines
The 2007 ESH/ESC guideline recognize 5 major antihy-
pertensive drug classes – thiazide diuretics, CCBs, ACEi, 
ARBs, and betablockers – to be suitable for the initiation 
and maintenance of antihypertensive treatment.17 The JNC 
VII guidelines18 on the other hand recommend using thiazide 
diuretics first. Both guidelines agree however in recommend-
ing the use of particular drug classes based on the presence 
of compelling indications.
ACEi and ARBs are recommended for the largest variety 
of compelling indications (for a detailed overview see 
Table 1), with only minor compelling contraindications in 
patients with pregnancy, hyperkalemia, bilateral renal artery 
stenosis, and angioneurotic edema (ACEi only). Therefore 
both drug classes are used, as illustrated by data from different 
drug utilization studies,16,19 in 50% to 60% of patients.
Drug–drug combination therapy
According to the ESH/ESC guidelines,17 the following 
drug–drug combinations have been found to be effective 
and well tolerated in randomized efficacy trials: Thiazide 
diuretic plus ACEi, thiazide diuretic and ARB, CCB and 
ACEi, CCB and ARB, CCB and thiazide diuretic, and beta 
blocker and dihydropiridine CCBs. Thus, 4 out of 6 recom-
mended dual antihypertensive combinations are ACEi/ARB 
based (Figure 2).
The ACCOMPLISH study triggered a lively discussion 
about the relative importance of drug–drug combinations.20,21 
It was designed to test whether benazepril 40 mg combined 
with amlodipine 10 mg would result in stronger cardiovas-
cular event reduction than benazepril 40 mg/HCTZ 25 mg. 
Inclusion and exclusion criteria favored the selection of 
patients with compelling indications for the use of CCBs. 
The composite primary endpoint of cardiovascular morbidity 
and mortality was reduced by 19.6% in patients receiving 
benazepril/amlodipine versus benazepril/HCTZ (9.6 versus 
11.8%; hazard ratio [HR] 0.80, 95% CI 0.72–0.90). The 
secondary endpoint of death from cardiovascular causes, 
non-fatal myocardial infarction, and non-fatal stroke was 
reduced by 21% with a HR of 0.79 (95% CI 0.67–0.92). 
Side effects were generally however more frequent with 
amlodipine than with the thiazide diuretic. Unfortunately 
no similar comparative study of the ACCOMPLISH type 
exists for patients with compelling indications for thiazide 
diuretic use.22 At present the evidence base is weak for 
deciding which patient would benefit the most from either 
combination.
Law and Wald have suggested combining ACEi/ARBs 
with a low dose of any of the other drug classes to maximize 
BP lowering efficacy while maintaining a placebo-like 
tolerability.23 This recommendation was based on the meta-
analytic observation that both ACEi and ARBs maintain a 
particular low AE profile in doses up to 4 times standard dose. 
On the contrary all other drug classes (CCBs, betablockers, 
thiazides) showed a steep incline of side effects at higher 
doses, while the tolerability was good at half-standard or 
even at standard dose.
The common approach to control BP in hypertensive 
patients is to titrate monotherapy to full dose and to add 
another agent if BP is still high (Figure 3, green). Drugs 
might be exchanged if there is indication of non-response to 
a particular agent. More recently the ESH/ESC guidelines17 
introduced the concept of first-line combination therapy at 
low dose in patients with marked BP elevation, low target 
BPs, and high or very high cardiovascular risk (Figure 3, red). 
This has been shown to be effective and safe and tolerability 
of first-line combination therapy is excellent.24,25
Requirements for antihypertensive drugs
In summary, from a patient, physician, and societal 
perspective there is a clear need for drug–drug combinations 
which provide effective BP lowering, and display a low side 
effect profile and a high adherence of both physicians and 
patients with treatment. This would enable BP control to 
be increased considerably and would in turn not only save 
on hypertension-related morbidity (stroke, ischemic heart 
disease) and mortality but also on costs.
It has been calculated for the UK that achieving a systolic 
BP of 140 mmHg on a large scale would decrease stroke Vascular Health and Risk Management 2009:5 1046
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Table 1 Compelling indications and contraindications in the use of antihypertensive drug classes17
  Conditions favoring use Compelling or possible contraindications
Thiazide diuretics •    isolated systolic hypertension (elderly) •    Gout
•    Heart failure •    Metabolic syndrome
•    Hypertension in blacks •    Glucose intolerance
•    Pregnancy
Beta blockers •   Angina pectoris •   Asthma
•    Post-myocardial infarction •   A-V block (grade 2 or 3)
•    Heart failure •    Peripheral artery disease
•   Tachyarrhythmias •    Metabolic syndrome
•    Glaucoma •    Glucose intolerance
•    Pregnancy •    Athletes and physically active patients
•    Chronic obstructive pulmonary disease
Calcium antagonists (dihydropyridines) •    isolated systolic hypertension (elderly) •    Tachyarrhythmias
•   Angina pectoris •    Heart failure
•    LV hypertrophy
•    Carotid/coronary atherosclerosis
•    Pregnancy
•    Hypertension in blacks
Calcium antagonists (verapamil/diltiazem) •   Angina pectoris •   A-V block (grade 2 or 3)
•    Carotid atherosclerosis •    Heart failure
•    Supraventricular tachycardia
ACe inhibitors •    Heart failure •    Pregnancy
•    LV dysfunction •   Angioneurotic edema
•    Post-myocardial infarction •    Hyperkalemia
•    Diabetic nephropathy •    Bilateral renal artery stenosis
•    Non-diabetic nephropathy
•    LV hypertrophy
•    Carotid atherosclerosis
•    Proteinuria/microalbuminuria
•   Atrial fibrillation
•    Metabolic syndrome
Angiotensin receptor antagonists •    Heart failure •    Pregnancy
•    Post-myocardial infarction •    Hyperkalemia
•    Diabetic nephropathy •    Bilateral renal artery stenosis
•    Proteinuria/microalbuminuria
•    LV hypertrophy
•   Atrial fibrillation
•    Metabolic syndrome
•   ACei-induced cough
Diuretics (antialdosterone) •    Heart failure •    Renal failure
•    Post-myocardial infarction •    Hyperkalemia
Loop diuretics •    end stage renal disease
  •    Heart failure  Vascular Health and Risk Management 2009:5 1047
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incidence by up to 44% depending on age group considered 
and ischemic heart disease incidence up to 35%.15 Assuming 
that a reduction of stroke incidence of 9% and ischemic heart 
disease of 4% across age groups might actually be achievable, 
the annual saving to the NHS would be £255 million for 
stroke and £25 million for ischemic heart disease while 
investing £58 million into drugs (net benefit to the NHS 
£222 million) (Figure 4).
Candesartan/HCTZ
The fixed drug–drug combination of candesartan cilexetil in 
a dose up to 32 mg and HCTZ in a dose up to 25 mg fulfils 
Thiazide diuretics
β-blockers
α-blockers
ACE inhibitors
Calcium antagonists
Angiotensin receptor
antagonists
Figure 2 Four out of 6 recommended dual antihypertensive combination therapies include blockers of the renin–angiotensin system.
Notes: Red, recommendation including an angiotensin receptor blocker; green, recommendations including an ACe inhibitor.
Reproduced with permission from Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management 
of  Arterial Hypertension of the european Society of Hypertension (eSH) and of the european Society of Cardiology (eSC).  J Hypertens. 2007; 25(6):1105–1187.17 Copyright © 
Lippincott williams & wilkins.
Choose between Mild BP elevation
Low/moderate CV risk
Conventional BP target
Single agent
at low dose
Previous agent
at full dose
Switch to different agent
at low dose
If goal BP not achieved
If goal BP not achieved
Previous combination
at full dose
Add a third drug
at low dose
Two-drug combination
at low dose 
Two- to three-drug combination
at full doses 
Two- to three-drug 
combination at full dose
Marked BP elevation
High/very high CV risk
Lower BP target
Full dose
monotherapy
Figure 3 Combination therapy as an escalation option and as first-line therapy.
Notes: Green, 2-drug combination therapy as an option for treatment escalation; red, 2-drug combination as a first line option in patients with marked elevation of blood 
pressure and high cardiovascular risk.
Reproduced with permission from Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management 
of Arterial Hypertension of the european Society of Hypertension (eSH) and of the european Society of Cardiology (eSC).  J Hypertens. 2007; 25(6):1105–1187.17 Copyright © 
Lippincott   williams &   wilkins.Vascular Health and Risk Management 2009:5 1048
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most of the above-mentioned requirements for improving 
BP control and related morbidity on a larger scale.
Candesartan
Candesartan is an ARB that is administered orally as 
candesartan cilexetil; it is rapidly and completely converted 
to candesartan, the active compound, during absorption 
from the upper gastrointestinal tract.26 It is characterized by 
a strong binding affinity to the angiotensin II type 1 receptor 
and its slow dissociation. Its binding to the AT1 receptor is 
insurmountable, meaning that it cannot be overcome by high 
concentrations of angiotensin II and, under physiological 
conditions, may even not dissociate until the AT1 receptor 
is recycled.26
Twenty-four hours after administration to healthy volun-
teers, the angiotensin II inhibiting activity per milligram of 
candesartan was stronger than that shown by other ARBs.27 
The trough-to-peak ratio is almost 90% (mean of all doses 
available). After a missed dose of candesartan, losartan, or 
placebo, 48-hour post-dose significant reductions of BP have 
been observed with candesartan 16 mg daily but not with 
losartan or placebo.28
Candesartan, applied as oral monotherapy, results in 
a strong dose-dependent reduction of both SBP and DBP 
between 4 and 16 mg, levelling off at 32 mg, and reaching 
its maximum at 8 weeks after treatment initiation.29,30 In a 
direct comparison of 16 mg candesartan and 20 mg enalapril 
candesartan was significantly more effective in reducing SBP 
and DBP (–13.5/–8.7 versus –9.9/–5.8 mmHg; P = 0.008).31 
It was also shown that BP returned to baseline after a missed 
dose of enalapril (–7.2/–4.5 mmHg) earlier than after a 
missed dose of candesartan (–11.4/–8.0 mmHg; P = 0.0002). 
Candesartan (up to 16 mg) and losartan (up to 50 mg) 
were compared in an 8-week study.32 Candesartan reduced 
diastolic BP by 8.9 and 10.3 mmHg with the 8 and 16 mg 
doses, respectively, while the BP reduction with losartan 
50 mg was 3.7 mmHg, the latter comparison reaching 
statistical significance (P = 0.013). Twenty-four hours after 
the ingestion of candesartan 100% of the peak SBP/DBP 
lowering effect was preserved (trough/peak ratio about 100% 
both systolic and diastolic) while only 70% of the losartan 
effect was preserved (trough/peak ratio 70% both systolic 
and diastolic).32 These data were essentially confirmed by 
Lacourciere et al which also demonstrated, that after a missed 
dose of 16 mg candesartan, the effect was well preserved 
after 36 hours, while the effect of 100 mg losartan was 
significantly reduced.28
It is tempting to speculate that differences in effectiveness 
of these ARBs may reflect pharmacologic and pharmacoki-
netic differences. The elimination half-life of candesartan 
is longer than that of losartan and its active metabolite. 
Candesartan cilexetil produces clear dose-dependent anti-
hypertensive effects, whereas it has been difficult to dem-
onstrate this property for losartan.26,32
Hydrochlorothiazide
HCTZ mainly acts within the lumen of the distal nephron, 
blocking the luminal transmembrane-coupled sodium 
chloride transport system. The mechanism by which thiazide 
diuretics reduce BP is however not completely understood. 
It has been proposed that during long-term therapy, thiazides 
act by reducing total peripheral resistance probably through 
a direct vascular effect.33 It is important to note however 
that in vivo vasodilation was achieved at higher doses than 
those reached during long-term oral treatment.34 HCTZ 
treatment in patients with hypertension induced changes in 
Additional drug costs
58.4 million £
Savings from
reduced IHD
25.2 million £
Savings from reduced
stroke/IHD
280.4 million £
Net savings from
intensified treatment
221.9 million £
Savings from
reduced stroke
255.1 million £
Figure 4 Cost savings in the UK by intensifying antihypertensive drug treatment.15
Notes: Optimizing antihypertensive therapy in the UK will cost £58.4 million and will prevent costs due to prevented stroke/ischemic heart disease (iHD) of £280.4 million 
resulting in a net benefit of £221.9 million.Vascular Health and Risk Management 2009:5 1049
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plasma volume, cardiac output, mean arterial pressure, stroke 
volume, heart rate, and total peripheral resistance.33,35
HCTZ has a half-life of 8 to 15 hours on chronic use and 
a duration of action that is slightly longer.36 HCTZ 50 mg 
twice daily for 12 or 36 weeks, after a 4-week placebo run-in 
period, lowered mean arterial pressure in 13 patients with 
untreated essential hypertension and DBP  100 mmHg.35 
Compared with the mean baseline value (177.2 mmHg), 
these reductions were significant throughout the study 
duration.
BP reduction with candesartan/HCTZ 
versus placebo
Fixed dose combinations of candesartan and HCTZ are 
available in various doses. Candesartan 32 mg once daily 
has to be regarded as a high dose (4 times standard dose).23 
HCTZ 12.5 and 25 mg have to be regarded as a half-standard 
and standard dose, respectively. Therefore the available 
combinations fulfil the requirements suggested by Law and 
Wald23 for maximizing efficacy while maintaining a high 
tolerability.
The extent of BP reduction with candesartan/HCTZ 
depends on baseline BP and the dose used. A variety of 
combinations including 2, 4, 6, 8, 16, or 32 mg candesartan 
and 6.25, 12.5, or 25 mg HCTZ, respectively, has been 
tested in clinical trials versus respective monotherapies 
or placebo.25,37–41 Uen et al for example demonstrated that 
replacing previously ineffective antihypertensive drugs by 
candesartan/HCTZ in patients with uncontrolled arterial 
hypertension significantly reduced both BP and ST-segment 
depression during daily life.41 Taken together these studies 
have consistently shown that combinations of candesartan 
with HCTZ, administered orally once a day for 4 to 52 weeks, 
induced significant reductions in SBP and DBP from baseline 
in patients with mild, moderate, or severe hypertension.
In a recent study by Edes et al (baseline DBP 90–114 mmHg), 
mean reductions in SBP and DBP were significantly greater 
with candesartan 32/HCTZ 25 mg (21/14 mmHg) than with 
candesartan 32 mg alone (13/9 mmHg), HCTZ 25 mg alone 
(12/8 mmHg), or placebo (4/3 mmHg) (P  0.001 for all 
comparisons).39 The proportion of patients with controlled 
BP (SBP  140 mmHg and DBP  90 mmHg) at the end 
of this study was also significantly greater in the candesartan 
32/HCTZ 25 mg group (63%) than in the other treatment 
groups (P  0.001 for all comparisons).
Bönner investigated the efficacy of candesartan 32 mg 
in combination with HCTZ 12.5 or 25 mg in patients not 
optimally controlled using candesartan monotherapy.42 A total 
of 3521 patients with treated or untreated hypertension and 
sitting DBP of 90 to 114 mmHg were included. After a single 
blind run-in phase (2 weeks candesartan 16 mg followed by a 
6-week treatment with candesartan 32 mg) 1975 patients who 
still had DBP readings of 90 to 114 mmHg were randomized 
to an 8-week double-blind treatment with either candesartan 
32 mg alone or in combination with HCTZ 12.5 mg or 25 mg 
respectively. Mean BP (153/97 mmHg at baseline) was 
further reduced during the double-blind treatment phase by 
6.1/5.6 mmHg in the candesartan monotherapy group, by 
13.0/8.8 mmHg in the fixed combination with HCTZ 12.5 mg 
group, and by 15.5/10.0 mmHg in the fixed combination with 
HCTZ 25 mg group (P  0.01 for all between treatment 
comparisons) (Figure 5).
Bönner et al tested the first-line use of candesartan 
16 mg/HCTZ 12.5 mg in 166 patients with no prior phar-
macotherapy for a treatment duration of 6 weeks.25 Blood 
pressure was reduced by 38.1/29.4 mmHg with 40% of 
patients achieving a normalization of BP. Tolerability was 
good showing that first line combination therapy is feasible 
and safe.
BP reduction with candesartan/HCTZ 
versus losartan/HCTZ
Ohma et al compared fixed dose combinations of candesartan 
16/HCTZ 12.5 mg and losartan 50/HCTZ 12.5 mg in patients 
insufficiently controlled on previous monotherapy.43 BP at 
randomization was 159.5/98.4 mmHg and 160.5/98.5 mmHg, 
respectively. After 12 weeks there was a greater reduction 
of BP with candesartan/HCTZ (–19.4/–10.4) than with 
losartan/HCTZ (–13.7/–7.8 mmHg), the differences being 
statistically significant. Twelve patients withdrew in the 
candesartan/HCTZ group (8 due to AEs), and 17 in the 
losartan/HCTZ group (12 AEs).
König compared candesartan/HCTZ and losartan/HCTZ 
in a 6-week study.44 Twenty-four-hour postdose mean seated 
BP was reduced by 32.2/21.1 mmHg (systolic/diastolic) in 
the candesartan/HCTZ group and 23.8/14.9 mmHg in the 
losartan/HCTZ group (P  0.001). Blood pressure reductions 
48 hours postdose were 25.6/16.4 mmHg for candesartan/
HCTZ and 9.2/4.2 mmHg for losartan/HCTZ, with differ-
ences between treatments being highly significant in favor 
of candesartan/HCTZ (16.5/12.2 mmHg; P  0.001). Both 
treatments were well tolerated.
Tolerability/compliance
ARBs are generally regarded to be a drug class with high 
compliance/persistence.45 Persistence with antihypertensive Vascular Health and Risk Management 2009:5 1050
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medication (including candesartan) was compared between 
different drug classes and between substances within one 
drug class in an Australian analysis covering the years 
2004 to 2006.46 The database yielded information relating 
to 48,690 patients prescribed antihypertensive medication. 
The median persistence time was 20 months, which was 
also the median persistence with ARBs or ACEi. The 
median persistence with CCBs was considerably lower 
(median persistence time 7 months; -57%, P  0.001). 
There were further differences in persistence between indi-
vidual drugs in the respective classes, the best outcomes 
being with candesartan and telmisartan (10%–20% better 
than the other ARBs considered), perindopril (ACEi; 25% 
better other ACEi) and lercanidipine (CCB; 25% better 
than other CCBs). This high persistence was reflected in 
the recent DIRECT trial in that about 80% of patients 
were compliant with 32 mg candesartan even when being 
nominally normotensive.47,48
Candesartan/HCTZ is generally well tolerated in 
patients with mild to moderate hypertension. Combined 
data from 5 randomised, double-blind, placebo-controlled 
clinical trials indicated that AEs during candesartan/HCTZ 
therapy (up to 16 mg/25 mg once daily) are uncommon 
and only few were serious.49 Among patients receiving 
candesartan/HCTZ or placebo the incidence of serious 
AEs was 1.6 and 2.1%, respectively, while 3.3 and 2.7% of 
patients discontinued treatment because of AEs. The most 
common AEs were headache, back pain, dizziness, and 
respiratory infections.
Recent trials indicated that the AE profile of candesartan 
32 mg in combination with 12.5 or 25 mg HCTZ is 
comparable to the aforementioned observations.39,42 Bönner 
et al reported about 1% serious AEs that were independent 
of whether monotherapy with candesartan or combination 
therapy including HCTZ was considered. For metabolic 
parameters, a slight increase of serum ureate and serum 
creatinine was observed with the fixed combinations while 
other parameters were essentially unchanged (Table 2).42 
Edes et al reported a rate of serious AE for the fixed dose 
combination that was even lower compared to placebo 
(0.2% versus 3.1%), with overall AE rate ranging between 
23% and 25% for placebo, HCTZ, candesartan, and their 
combination.39
Mengden et al compared drug regimen compliance 
(DRC) with antihypertensive combination therapy in patients 
whose BP was controlled versus uncontrolled after 4 weeks 
of self-monitored BP measurement.50 Whether switching 
one drug of the combination therapy to candesartan/HCTZ 
(16 mg/12.5 mg) in uncontrolled patients with and without 
compliance intervention program would improve BP normal-
ization was also evaluated. It was found that normalization of 
BP was associated with superior drug regimen compliance 
in previously uncontrolled patients treated with a combina-
tion drug regimen. Switching still-uncontrolled patients to 
−18.0
−16.0
−14.0
−12.0
−10.0
−8.0
−6.0
−4.0
−2.0
0.0
Candesartan 32 mg
Candesartan 32/HCTZ
12.5 mg 
Candesartan 32/HCTZ
25 mg
SBP
DBP
Figure 5 Blood pressure reduction with 32 mg candesartan alone or in combination with 12.5 or 25 mg HCTZ in patients not sufficiently controlled on monotherapy.42Vascular Health and Risk Management 2009:5 1051
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candesartan/HCTZ significantly improved BP control and 
stabilized a declining DRC.
Patient types
Patients with heart failure
Heart failure is a frequent comorbidity in patients with 
hypertension. It is characterized by a decline in systolic or 
diastolic function, the latter being a typical complication 
of long-term uncontrolled hypertension. The fixed dose 
combination of candesartan/HCTZ has never been formally 
tested in this patient population, but the benefits of blocking 
the RAS and enhancing diuresis are basic concepts in the 
treatment of HF.51 HCTZ is recommended for the treatment 
of patients with HF in doses of 25 mg to initiate treatment 
and maintenance doses of between 2.5 and 100 mg daily.51 
Candesartan is recommended to be started at a dose of 
4 or 8 mg daily and uptitrated to a target dose of 32 mg.
The basis for the recommendation of candesartan was 
the results of the CHARM trial program.52 In CHARM 
candesartan was tested in patients with systolic HF given 
either on top of an ACEi53 or in cases of ACEi intolerance.54 
A third trial investigated the effect of candesartan in 
diastolic HF (HF with preserved systolic function).55 Overall, 
7601 patients were randomly assigned candesartan (titrated to 
32 mg once daily) or matching placebo, and followed up for 
at least 2 years. In the overall CHARM trial program 82.8% 
of patients in the candesartan arm and 82.6% of patients in 
the placebo arm received diuretics and a further 16.9 and 
16.6% respectively spironolactone.
In CHARM Alternative (candesartan given instead of 
an ACEi) treatment resulted in a relative risk reduction 
(RRR) of death from cardiovascular cause or hospital admis-
sion for worsening HF of 23% (ARR 7%, NNT 14, over 
34 months of follow-up, adjusted P  0.0001 (Figure 6).54 
In the CHARM Added trial (candesartan on top of existing 
ACEi therapy) candesartan cotreatment resulted in a 15% 
RRR of cardiovascular death or hospital admission for CHF 
(ARR 4%, NNT 25, over 41 months of follow-up, adjusted 
P = 0.010).54 The CHARM Preserved trial (candesartan in 
patients with HF but preserved systolic function) candesartan 
did not show a significant reduction in the risk of the primary 
composite endpoint (adjudicated death from cardiovascular 
causes or admission with HF) but did show a significant 
reduction in the number of patients admitted to hospital 
with CHF (ARR 3.3%, NNT 30, over 37 months follow up, 
P = 0.017).55
In summary it appears possible to initiate drug treatment 
of HF with both combination agents at low dose, uptitrate 
Table 2 Laboratory values at baseline, and mean change (±SD) from baselinea after 8 weeks of treatment42
  
 
Candesartan 32 mg 
n = 653 
Candesartan 32 mg 
12.5 mg HCTZ 
n = 654
Candesartan 32 mg 
25 mg HCTZ 
n = 664
S-urate (µmol/L)
  Baseline 334.5 (84.6) 335.2 (82.6) 339.1 (80.6)
  Change 5.1 (52.0) 27.4 (52.3) 43.9 (57.8)
S-potassium (mmol/L)
  Baseline 4.5 (0.4) 4.5 (0.4) 4.5 (0.4)
  Change 0.0 (0.4) 0.1 (0.4) -0.1 (0.4)
S-glucose (mmol/L)
  Baseline 6.0 (1.4) 6.2 (1.9) 5.9 (1.5)
  Change 0.0 (1.0) 0.4 (1.0) 0.0 (0.9)
S-triglycerides (mmol/l)
  Baseline 2.0 (1.4) 1.9 (1.8) 2.0 (1.5)
  Change 0.0 (1.2) 0.0 (1.6) 0.2 (2.2)
S-cholesterol (mmol/L)
  Baseline 5.8 (1.1) 5.8 (1.1) 5.9 (1.0)
  Change 0.1 (0.7) 0.0 (0.8) 0.1 (0.8)
S-creatinine (µmol/L)
  Baseline 79.8 (15.8) 79.9 (14.8) 80.3 (15.4)
  Change 0.0 (10.5) 1.8 (9.8) 4.5 (13.1)
aBaseline: after a run-in phase with 16 mg candesartan for 2 weeks and 32 mg candesartan for 6 weeks.Vascular Health and Risk Management 2009:5 1052
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candesartan and HCTZ as warranted and, should the doses fit, 
switch to a fixed dose combination of candesartan 32/HCTZ 
25 mg for maintenance treatment.
Patients with stroke
Stroke is a frequent, serious, and finally costly complication 
of hypertension. Candesartan was tested in 2 trials with 
respect to this indication, one testing the capability of 
preventing stroke or related disabilities (SCOPE,56 see 
section Elderly patients), the other testing cerebro- and 
cardiovascular endpoints in patients with a history of stroke 
(ACCESS).57
ACCESS was designed to evaluate the safety of early 
antihypertensive treatment in patients with acute cere-
bral ischemia).57 Patients with motor paresis and initial 
SBP  200 mmHg and/or DBP  110 mmHg or mean 
BP of 2 measurements 180 mmHg and/or 105 mmHg, 
respectively, were included. The trial was stopped prema-
turely after the recruitment of 349 patients due to an imbal-
ance in endpoints. Cumulative 12-month mortality and the 
number of vascular events differed significantly in favor of 
the candesartan group (OR 0.475; 95% CI 0.252–0.895). 
There were no cardiovascular or cerebrovascular events as 
a result of hypotension. Treatment was started with 4 mg 
candesartan daily on day 1. On day 2, dosage was increased 
to 8 or 16 mg candesartan if BP exceeded 160 mmHg 
systolic or 100 mmHg diastolic. In patients in the cande-
sartan group who were still hypertensive on day 7 (mean 
daytime BP  135/85 mmHg), candesartan was increased 
or an additional antihypertensive drug (HCTZ, felodipine, 
metoprolol) was added. The control group received placebo 
for the first 7 days and 8 to 16 mg candesartan throughout 
the rest of the study.
In the ongoing SCAST trial (NCT00120003) candesartan 
is tested in patients with stroke (ischemic or hemorrhagic) 
and SBP  140 mmHg. Patients receive 4 mg candesartan 
on day 1; 8 mg on day 2; 16 mg on days 3 to 7. Dose adjust-
ment in cases of SBP  120 mmHg, or symptomatic fall in 
BP are mandated. From day 8 therapies can be supplemented 
with any antihypertensive agent including diuretics.
Taken together there is good evidence that early cande-
sartan treatment after acute stroke might be able to prevent 
vascular events and mortality. The fixed dose combination 
might be useful after several days of candesartan mono-
therapy uptitration after which HCTZ in low dose is added 
to maintain or achieve BP control.
Patients with diabetes mellitus
Antihypertensive treatment in diabetic patients is complicated 
by the fact that baseline BP readings are usually high, while 
having to meet lower BP goals (130/80 mmHg in most 
cases).17 ARBs are beneficial within the context of diabetes 
because they have been shown to delay the development of 
diabetes more than any other drug class (Figure 7)58,59 and to 
be at least neutral or even beneficial with respect to metabolic 
parameters. As has been shown in a number of clinical trials, 
the reduction of cardiovascular morbidity following antihy-
pertensive treatment is usually, but not always, pronounced 
in patients with diabetes.60,61
Candesartan reduced the number of patients developing 
diabetes in the CHARM,62 SCOPE,63 and ALPINE trials.64 
When administered to a group of hypertensive subjects it 
p = 0.032 p < 0.0001
p < 0.0001 p = n.s.
p = n.s.
p = n.s.
p = 0.010
p = n.s.
All-cause mortality*
Alternative
Added
Preserved
Overall
Hazard ratio
0.7 0.8 0.9 1.0 1.1 1.2 0.7 0.6 0.8 0.9 1.0 1.1 1.2
Hazard ratio
Cardiovascular death
or hospital admission
for CHF†
Figure 6 Results of the CHARM trial program.52–55
Notes: *p for heterogeneity 0.37; †p for heterogeneity 0.33.
Reprinted from Pfeffer MA, Swedberg K, Granger CB, et al. effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall 
programme. The Lancet. 362:759–766.52 Copyright © 2003, with permission from elsevier.Vascular Health and Risk Management 2009:5 1053
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reduced C-reactive protein and increased adiponectin and 
markers of insulin sensitivity, as measured by QUICKI 
(Quantitative Insulin-Sensitivity Check Index).65
It also reduced BP effectively in diabetic patients.66 
Bramlage et al demonstrated in an observational study in 
primary care that candesartan 16/HCTZ 12.5 mg lowered 
BP effectively in patients with and without diabetes.45 The 
absolute amount of BP lowering (–27.2/–1–3.4 mmHg) 
appeared to be dependent on baseline BP but did not 
differ among patient types (diabetes, metabolic syndrome, 
or neither condition).
Microalbuminuria in diabetes is strongly predictive 
of nephropathy, end-stage renal disease, and premature 
cardiovascular morbidity and mortality. Effective preven-
tive therapies are therefore a clinical priority. The effect 
of candesartan in the prevention of microalbuminuria was 
tested in a pooled analysis of the DIRECT trial program in 
which normotensive patients with type 1 (n = 3326) and 
2 (n = 1905) diabetes were included.67 Due to the study design 
the incidence of microalbuminuria was low in this analysis 
and no differences in the risk for albuminuria were noted 
(HR 0.95; 95% CI 0.78–1.16). Pooled results showed that 
the annual rate of change in albuminuria was 5.53% lower 
(CI, 0.73%–10.14%; P = 0.024) with candesartan than with 
placebo. Studies conducted by Trenkwalder68 and Mogensen69 
have however shown that candesartan is effective in lowering 
the level of albumin excretion in patients with hypertension, 
diabetes, and already existing microalbuminuria. Taking a 
much higher than recommended dose of the hypertension 
drug candesartan was shown to effectively lower the amount 
of protein excreted in the urine of patients with kidney disease 
in a study by Burgess et al.70 269 patients with persistent 
proteinuria despite treatment with 16 mg candesartan were 
randomized to receive 16, 64, or 128 mg daily of candesartan 
for 30 weeks. It was found that patients taking 128 mg of 
candesartan experienced a 33% reduction in proteinuria 
compared with those receiving 16 mg candesartan by the 
end of the study. There is however a missing link between 
microalbuminuria reduction and morbidity and mortality 
endpoints which have so far been reported only from post-hoc 
analyses. A respective study is however already underway to 
provide this link.71 Important in this respect are the results 
of the GUARD study that combined an ACEi with either 
amlodipine or HCTZ and demonstrated that with HCTZ 
the nephroprotective effect of benazepril was preserved 
while it was reduced when amlodipine was chosen as the 
combination partner.72
The DIRECT trial program was a series of clinical 
trials investigating the effect of candesartan on the develop-
ment and progression diabetic retinopathy who were either 
normotensive or had treated hypertension.47,73 DIRECT 
consisted of three randomized, double-blind, placebo-
controlled multicenter studies designed to investigate the 
potential for candesartan in halting the progression of, and 
possibly prevent, diabetic retinopathy. Results showed that 
candesartan was beneficial for patients with type 2 diabetes 
who had established mild to moderate retinopathy, because 
candesartan had an additional, BP-independent effect on 
improvement of retinopathy (Figure 8). Candesartan was 
also shown to be indicated for patients with type 1 diabetes 
Treatment Odds ratio
(95% CI of incident diabetes)
ARBs
ACE inhibitors
Calcium-channel blockers
β blockers
Diuretics
0.50 0.80 1.00 1.25 2.00
Favours treatment Favours placebo
0.822 (0.679–0.999)
0.889 (0.765–1.036)
1.051 (0.893–1.263)
1.250 (1.055–1.503)
1.347 (1.133–1.632)
Figure 7 Development of diabetes – results of a meta-analysis.
Reprinted from Lam SK, Owen A. incident diabetes in clinical trials of antihypertensive drugs. The Lancet. 369:1513–1514.59 Copyright © 2007, with permission from elsevier.Vascular Health and Risk Management 2009:5 1054
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without retinopathy, in order to reduce their risk of developing 
retinopathy.
In summary there is an abundance of evidence for the 
use of candesartan in patients with diabetes or a high risk for 
developing such. Data on the use of a fixed dose combination 
of candesartan/HCTZ are scarce, leaving it unproven that a 
combination treatment is likewise beneficial. Data addressing 
the dysmetabolic potential have however shown that the 
metabolic profile of HCTZ is neutralized when adding cande-
sartan. Because of the need for multiple drug–drug combina-
tions there is a clear need for combination therapy including 
diuretics, which are favored in common co-morbidities of 
diabetes, eg, CHF or diabetic nephropathy.
elderly patients
The pharmacokinetics of candesartan were investigated after 
single and repeated once-daily doses in a trial by Hübner et al74 
of candesartan in the dose range 2 to 16 mg in both younger 
(19–40 years) and elderly (65–78 years) healthy volunteers. 
The area under the curve (AUC) and maximal concentration 
(Cmax) of candesartan showed dose-proportional increases in 
the dose range of 2 to 16 mg candesartan after both single and 
repeated once-daily tablet intake, indicating linear pharma-
cokinetics in both younger and elderly healthy subjects. The 
time to peak candesartan concentrations after tablet intake 
was consistently approximately 4 hour at all dose levels. Only 
mild AEs were recorded, with ‘headache’ the most commonly 
reported event, and no increase in the number of reported AEs 
was observed with higher doses of candesartan cilexetil.74
Results of the SCOPE study implied that candesartan 
treatment reduces cardiovascular morbidity and mortal-
ity in old and very old patients with mild to moderate 
hypertension.75,76 Candesartan-based antihypertensive treat-
ment may also have positive effects on cognitive function 
and quality of life. SCOPE was a multi-center, prospective, 
randomized, double-blind, parallel-group study. The primary 
objective was to assess the effect of candesartan 8–16 mg 
once daily, on major cardiovascular events in elderly patients 
(70–89 years of age) with mild hypertension (DBP 90–99 
and/or SBP 160–179 mmHg). The main analysis showed 
that non-fatal stroke was reduced by 28% (P = 0.04) in the 
candesartan group compared with the control group, and there 
was a non-significant 11% reduction in the primary endpoint, 
major cardiovascular events (P = 0.19). Significant risk reduc-
tions with candesartan in major cardiovascular events (32%, 
P = 0.013), cardiovascular mortality (29%, P = 0.049) and 
total mortality (27%, P = 0.018) were observed in patients 
who did not receive add-on therapy after randomization, 
and in whom the difference in BP was 4.7/2.6 mmHg. Other 
analyzes suggest positive effects of candesartan-based treat-
ment on cognitive function, quality of life and new-onset dia-
betes. Results of SCOPE strongly suggested that candesartan 
treatment reduces cardiovascular morbidity and mortality in 
old and very old patients with mild to moderate hypertension. 
Candesartan-based antihypertensive treatment may also have 
positive effects on cognitive function and quality of life.76
Subgroup analyses from the CHARM study in patients 
with HF showed that older patients were at a greater absolute 
Changes in the ETDRS Scale at study end compared to baseline
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risk of adverse CV mortality and morbidity outcomes, but 
derived a similar RRR and, therefore, a greater absolute 
benefit from treatment with candesartan, despite receiving 
a somewhat lower mean daily dose of candesartan.77 
Adverse effects were more common with candesartan than 
with placebo, although the relative risk of adverse effects 
was similar across age groups. The benefit to risk ratio for 
candesartan was thus favorable across all age groups.
In summary, given that diuretics are frequently indicated 
in elderly patients there appears to be a role for fixed dose 
combinations of candesartan/HCTZ. But again evidence has 
been acquired with free combinations of candesartan with 
other antihypertensive drugs including thiazide diuretics.
Economic evaluation
The addition of candesartan to standard therapy for CHF pro-
vided important clinical benefits at little or no additional cost 
in France, Germany, and the UK, according to a detailed eco-
nomic analysis focusing on major cardiovascular events and 
prospectively collected resource-use data from the CHARM-
Added and CHARM-Alternative trials in patients with CHF 
and left ventricular (LV) systolic dysfunction.78 Results of a 
corresponding cost-effectiveness analysis showed that can-
desartan was either dominant over placebo or was associated 
with small incremental costs per life-year gained, depending 
on the country and whether individual trial or pooled data 
were used. Preliminary data from a US cost-effectiveness 
analysis based on CHARM data also showed favorable results 
for candesartan cilexetil. Two cost-effectiveness analyses of 
candesartan cilexetil in hypertension have been published, 
both conducted in Sweden.
Data from the SCOPE trial in elderly patients with 
hypertension, which showed a significant reduction in 
non-fatal stroke with candesartan-based therapy versus 
non-candesartan based treatment, were incorporated into a 
Markov model and an incremental cost-effectiveness ratio 
of  12,824 per QALY gained was calculated (2001 value).
In conclusion, despite some inherent limitations, economic 
analyses incorporating CHARM data and conducted primarily 
in Europe have shown that candesartan cilexetil appears to 
be cost-effective when added to standard CHF treatment in 
patients with CHF and compromised LV systolic function. 
The use of candesartan cilexetil as part of antihypertensive 
therapy in elderly patients with elevated BP was also deemed 
to be cost effective in a Swedish analysis, primarily resulting 
from a reduced risk of non-fatal stroke (as shown in the 
SCOPE study); however, the generalizability of results to 
other contexts has not been established. Cost-effectiveness 
analyses comparing candesartan cilexetil with ACE inhibitors 
or other angiotensin receptor blockers in CHF or hypertension 
are lacking, and results reported for candesartan cilexetil in 
a Swedish economic analysis of ALPINE data focusing on 
outcomes for diabetes require confirmation and extension.
Conclusions
The fixed dose combination of candesartan and HCTZ is 
a valuable addition to the armamentarium of drugs in the 
treatment of hypertension, because of its high efficacy in 
reducing BP, its tolerability, and the high compliance of 
patients with treatment. Comparative studies with losartan/
HCTZ have consistently shown a higher clinical efficacy with 
the candesartan/HCTZ combination. Candesartan/HCTZ 
therefore assists both physicians and patients in achieving 
long-term treatment goals.
Data on the reduction of cardiovascular endpoints with 
fixed dose combinations of antihypertensive drugs are 
scarce, as are the data for candesartan/HCTZ. However many 
trials have tested candesartan versus a non-RAS blocking 
comparator based on a standard therapy including thiazide 
diuretics. The indications tested were HF and stroke, and 
particular emphasis was put on elderly patients or those with 
diabetes. In patients with HF, for example, the fixed dose 
combination might be applied in patients in whom indi-
vidual titration resulted in a dose of 32 mg candesartan and 
25 mg HCTZ which can then be combined into one tablet 
to increase compliance with treatment. Also in patients with 
stroke the fixed dose combination might be used in patients 
in whom maintenance therapy with both components is 
considered.
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